Navigation Links
FDA Approves NovoLog(R) Labeling Update
Date:7/15/2009

ons by syringe.

Tell your health care provider about all medicines you take and all of your medical conditions, including if you are pregnant or breastfeeding. Your NovoLog(R) dose may change if you take other medicines.

NovoLog(R) has not been studied in children with type 2 diabetes or in children with type 1 diabetes under the age of two.

The most common side effect of NovoLog(R) is low blood sugar (hypoglycemia). Other possible side effects include reactions at the injection site (like redness, swelling and itching), and allergic reactions. Get medical help right away if you experience signs of serious allergic reaction such as body rash, trouble with your breathing, fast heartbeat, or sweating. Ask your doctor or pharmacist for further information.

About Novo Nordisk

Novo Nordisk is a healthcare company with an 86-year history of innovation and achievement in diabetes care. The company has the broadest diabetes product portfolio in the industry, including the most advanced products within the area of insulin delivery systems. In addition to diabetes care, Novo Nordisk has a leading position within areas such as hemostasis management, growth hormone therapy, and hormone therapy for women. Novo Nordisk's business is driven by the Triple Bottom Line: a commitment to economic success, environmental soundness, and social responsibility to employees and customers. With headquarters in Denmark, Novo Nordisk employs more than 27,000 employees in 81 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For global information, visit novonordisk.com; for United States information, visit www.novonordisk-us.com.

(1) Revised NovoLog Prescribing Information. "Dos
'/>"/>

SOURCE Novo Nordisk
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine news :

1. Fitness Management Group, Inc. Approves Sale of the Company
2. Cardinal Health Board of Directors Approves CareFusion Spinoff
3. Video: FDA Approves Hologics Adiana(R) Permanent Contraception System
4. European Medicines Agency (EMEA) Approves Cell Therapeutics, Inc.s September Meeting Request to Discuss OPAXIO(TM) Marketing Authorization Application
5. FDA Approves Multaq(R) for Patients with Atrial Fibrillation or Atrial Flutter
6. FDA Approves Lamictal(R)XR(TM); An Extended-Release Once-Daily, New Generation Treatment for Epilepsy
7. FDA Approves Reclast(R) to Prevent Osteoporosis in Postmenopausal Women With Convenient Less Frequent Dosing
8. FDA Approves SAMSCA(TM) (tolvaptan), the First and Only Oral Vasopressin Antagonist to Treat Patients With Clinically Significant Hypervolemic and Euvolemic Hyponatremia
9. ClearWay Minnesota(SM) Board Approves Four Regional Grants
10. Department of Defense Approves ISSA as Fitness Education Provider to Military Spouses
11. FDA Approves ACTOplus met(R) XR (pioglitazone HCl and metformin HCl extended-release) Tablets for the Treatment of Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
Other Medicine News:Health News:Partnership for a Drug-Free America(R) Responds to 2008 Monitoring the Future Study Results 2Health News:Partnership for a Drug-Free America(R) Responds to 2008 Monitoring the Future Study Results 3Health News:Betty White's Video States Support for Funding Humane Research to Help Pets and Wild Animals - Actress is 40-Year Champion of Morris Animal Foundation 2Health News:Hallmark Hall of Fame Collaboration with Patient Organization Equals Extraordinary Success 2Health News:Playing Video Games May Boost Older Brains 2Health News:Playing Video Games May Boost Older Brains 3Health News:Cancer drugs in the pipeline 2Health News:Combination of TYKERB(R) (lapatinib) Plus Letrozole Demonstrated Significant Improvement in Delaying Disease Progression for HER2+/ErbB2+ Post-Menopausal Metastatic Breast Cancer 2Health News:Combination of TYKERB(R) (lapatinib) Plus Letrozole Demonstrated Significant Improvement in Delaying Disease Progression for HER2+/ErbB2+ Post-Menopausal Metastatic Breast Cancer 3Health News:Combination of TYKERB(R) (lapatinib) Plus Letrozole Demonstrated Significant Improvement in Delaying Disease Progression for HER2+/ErbB2+ Post-Menopausal Metastatic Breast Cancer 4Health News:Combination of TYKERB(R) (lapatinib) Plus Letrozole Demonstrated Significant Improvement in Delaying Disease Progression for HER2+/ErbB2+ Post-Menopausal Metastatic Breast Cancer 5Health News:Combination of TYKERB(R) (lapatinib) Plus Letrozole Demonstrated Significant Improvement in Delaying Disease Progression for HER2+/ErbB2+ Post-Menopausal Metastatic Breast Cancer 6Health News:Combination of TYKERB(R) (lapatinib) Plus Letrozole Demonstrated Significant Improvement in Delaying Disease Progression for HER2+/ErbB2+ Post-Menopausal Metastatic Breast Cancer 7
Breaking Medicine Technology:Royalty Pharma Announces that Alexander von Perfall Joins Management Team 2ThermoGenesis Announces Agreement for Adipose Tissue Clinical Program 2ThermoGenesis Announces Agreement for Adipose Tissue Clinical Program 3ThermoGenesis Announces Agreement for Adipose Tissue Clinical Program 4Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 2Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 3Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 4Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 5Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 6Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 7SEQUENOM Announces Launch of SensiGene Cystic Fibrosis Carrier Screening Test 57495 1SEQUENOM Announces Launch of SensiGene Cystic Fibrosis Carrier Screening Test 57495 2SEQUENOM Announces Launch of SensiGene Cystic Fibrosis Carrier Screening Test 57495 3SEQUENOM Announces Launch of SensiGene Cystic Fibrosis Carrier Screening Test 57495 4SEQUENOM Announces Launch of SensiGene Cystic Fibrosis Carrier Screening Test 57495 5SEQUENOM Announces Launch of SensiGene Cystic Fibrosis Carrier Screening Test 57495 6African Americans at Significantly Higher Risk of DVT or Blood Clots 57491 1African Americans at Significantly Higher Risk of DVT or Blood Clots 57491 2African Americans at Significantly Higher Risk of DVT or Blood Clots 57491 3African Americans at Significantly Higher Risk of DVT or Blood Clots 57491 4Rigel Announces Pricing of Public Offering of 13 000 000 Shares of Common Stock 14119 1Rigel Announces Pricing of Public Offering of 13 000 000 Shares of Common Stock 14119 2